Direvo Biotech AG

In the last five years, the average up-front return on investment in private biotech acquisitions has declined from 4x in 2006 to under 2x thus far in 2010, thanks primarily to the rise in earn-out-he

Attention deficit hyperactivity disorder (ADHD) Alzheimer's disease Anxiety Depression Epilepsy Huntington's disease Insomnia Pain Schizophrenia Other Source: Scrip analysis

Bayer is adamant that it will avoid billion-dollar transactions in healthcare this year and has no interest in buying a generics business. Instead it will focus on developing external links with resea

Already hit hard by a difficult regulatory and reimbursement climate, the pace of venture investing in biotechnology has slowed to a crawl because of the global financial crisis. How bad is it, and wh